Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTMBiotechnology
+$3.42 today
- Market cap
- $8.25B
- Beta
- 1.92
- P/E (TTM)
- -33.3
- EPS (TTM)
- -$2.98
Volume 2.01M
Average 0.81M
RYTM Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation dips below year-ago levels
Q3 FY2026 stock-based compensation of $1.93M fell 89.8% year over year, behind the +60.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 96.1% from the prior quarter. Over 3 fiscal years it compounded at +49.9% a year.
Context
- Stock-based compensation amounted to 35.2% of revenue in FY2025, up 4.7 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -89.8% toward the trailing-twelve-month pace of +60.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 66.82M USD
- Year-over-year change
- +68.4%
- 4-year CAGR
- +33.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 66.82M | +68.4% |
| FY2024 | 2024-12-31 | 39.68M | +21.9% |
| FY2023 | 2023-12-31 | 32.55M | +64.2% |
| FY2022 | 2022-12-31 | 19.83M | -4.7% |
| FY2021 | 2021-12-31 | 20.8M | — |
Stock-Based Compensation vs competitors
How RYTM compares with its peers on the latest reported figures
- RYTM's LTM Sep 2026 stock-based compensation of $93.45M is the 2nd largest of the 11 companies compared; the peer median is $19.98M.
- Its year-over-year change of +60.8% is the 7th highest of 11, against a peer median of +97.8%.
- Stock-based compensation amounts to 33.3% of revenue for RYTM, versus a peer median of 20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $172.73B | +92559.3% | -2.6% | 16.8% | |
| LTM Sep 2026 | $93.45M | +60.8% | +49.9% | 33.3% | |
| LTM Jun 2026 | $51.48M | +103.6% | +125.9% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $41.75M | +456.0% | +204.9% | — |
| LTM Jun 2026 | $37.39M | -5.4% | +67.6% | — | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $19.67M | +177.6% | +77.3% | 20.4% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M | +43.2% | +66.3% | 126.0% |
| LTM Mar 2026 | $4.16M | -75.9% | -2.7% | — | |
| LTM Mar 2026 | $1.24M | -22.2% | -18.0% | 9.6% | |
BLTEBelite Bio, Inc | LTM Jun 2026 | $45.7K | +408.5% | +197.2% | — |
| Peer median (excluding RYTM) | $19.98M | +97.8% | +67.0% | 20.4% | |
Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (69.61M) | (181.12M) | (184.68M) | (260.6M) | (196.54M) |
| Depreciation & Amortization | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M |
| Deferred Income Tax | (100M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.8M | 19.83M | 32.55M | 39.68M | 66.82M |
| Change in Working Capital | 1.9M | (19.72M) | 4.81M | 10.58M | (968K) |
| Accounts Receivables | (1.25M) | (5.2M) | (8.64M) | (3.65M) | (7.57M) |
| Inventory | (11K) | (2.81M) | (5.71M) | (10.12M) | (7.47M) |
| Accounts Payables | 18.31M | 1.54M | 14.77M | 21.92M | 21.89M |
| Other Working Capital | (15.15M) | (13.26M) | 4.38M | 2.42M | (7.82M) |
| Other Non-Cash Items | (250K) | 5.91M | 9.4M | 94.9M | 13.68M |
| Operating Cash Flow | (146M) | (173.43M) | (136.16M) | (113.88M) | (115.68M) |
| Capital Expenditures | (5.43M) | (4.28M) | (47K) | 0 | (953K) |
| Acquisitions (Net) | 100M | 4M | 0 | 0 | 0 |
| Purchases of Investments | (524.97M) | (251.94M) | (354.92M) | (268.31M) | (348.67M) |
| Sales of Investments | 361.25M | 284.25M | 354.97M | 260.64M | 252.47M |
| Other Investing Activities | 7M | (4M) | (5.67M) | (40.5M) | (40M) |
| Investing Cash Flow | (62.16M) | 28.03M | (5.67M) | (48.17M) | (137.15M) |
| Debt Repayment | 0 | 0 | 0 | (12.9M) | 0 |
| Common Stock Issued | 161.73M | 131.11M | 48.88M | 195.24M | 237.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (3.97M) | 0 |
| Other Financing Activities | 4.76M | 82.72M | 25.49M | 12.87M | (19.92M) |
| Financing Cash Flow | 166.48M | 213.83M | 74.37M | 191.24M | 217.96M |
| Effect of Forex Changes | 0 | 0 | (142K) | 2K | 87K |
| Net Change in Cash | (41.68M) | 68.43M | (67.6M) | 29.19M | (34.78M) |
| Free Cash Flow | (151.44M) | (177.71M) | (136.2M) | (113.88M) | (116.63M) |
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
Intrinsic Alpha fair value
Locked
Current Price
$119.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.